MHY1485 is an mTOR activator that is cell-permeable. MHY1485 inhibits autophagosome and lysosome fusion, leading to accumulation of LC3II proteins and increased autophagosomes, thereby inhibiting cellular autophagy.

METHODS: MDA-MB-231, BT-20, MDA-MB-468 cells and T cells were co-cultured and treated with Atezolizumab (50-100 µg/mL) for 4-24 h. T cell-mediated cytotoxicity assay was performed.
RESULTS: Atezolizumab significantly enhanced T cell-mediated cytotoxicity of MDA-MB-231 cells in a dose-dependent manner, with 100 µg/mL concentration of Atezolizumab showing significant efficacy at 4 and 24 h incubation. Similar results were obtained with BT-20. No Atezolizumab-induced T cell-mediated cytotoxicity was observed in PD-L1- MDA-MB-468 cells compared to MDA-MB-231 and BT-20 cells. [1]
METHODS: MDA-MB-231 cells were treated with Atezolizumab (0.5 µg/mL) for 24 h. Surface expression of PD-L1 was detected by flow cytometry.
RESULTS: Almost all MDA-MB-231 cells were positive for PD-L1, but detection of PD-L1 epitopes was blocked by the specific antibody Atezolizumab after 24 h treatment. [2]

METHODS: To detect in vivo antitumor activity, Atezolizumab (10 mg/kg) and Bevacizumab (5 mg/kg) were intraperitoneally injected into BALB/C nude mice bearing A2780cis xenografts every two days for three weeks.
RESULTS: In vivo treatment with Atezolizumab or Bevacizumab induced significant antitumor effects and significantly inhibited tumor growth. Dual blockade with Atezolizumab and Bevacizumab significantly inhibited tumor growth compared to each treatment. [3]

Ovaries from mice at day10 of age are treated with 10 μM MHY1485 for 3h and proteins are extracted using M-PER Mammalian Protein Extraction Reagent containing a protease inhibitor cocktail. Protein concentrations in supernatants are determined by the bicinchoninic acid method. Equal amounts of protein lysates are loaded on 4-12% NuPAGE Bis-Tris gels in MOPS buffer and transferred to 0.45 μM pore nitrocellulose membranes[2].

MHY1485 is dissolved in DMSO and then diluted with appropriate media[3]. MC3T3-E1 cells are maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin at 37°C in a humidified atmosphere of 5% CO2. Having reached 70% confluence, the culture medium is switched to commercial osteogenic differentiation medium. MC3T3-E1 cells are cultured in the osteogenic differentiation medium for 14 days, following by culture in DMEM supplemented with varying concentrations of liraglutide for a further 14 days. MC3T3-E1 cells treated with 4 nM liraglutide are cultured in the presence or absence of Compound C or MHY1485. MC3T3-E1 cells maintained in DMEM for 28 days in the absence of any treatment are used as the negative control (NC); cells cultured in commercial osteogenic differentiation medium for 14 days and in DMEM without liraglutide for an additional 14 days are used as the positive control (PC)[3].